Erratum: Identification of a novel selective agonist of PPARÎ 3 with no promotion of adipogenesis and less inhibition of osteoblastogenesis (Scientific Reports (2015) 5:9530 DOI: 10.1038/srep09530);Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Chang ^a   Feng, Tingting ^a   Zhu, Ningyu ^a   Liu, Peng ^a   Han, Xiaowan ^a   Chen, Minghua ^a   Wang, Xiao ^a   Li, Ni ^a   Li, Yongzhen ^a   Xu, Yanni ^a   Si, Shuyi ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-(2-(1,2-DIMETHYL-1H-INDOL-3-YL)-2-OXOACETYLAMINO)BENZAMIDE; BENZAMIDE DERIVATIVE; CYCLIN DEPENDENT KINASE 5; INDOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BINDING; ROSIGLITAZONE;

3T3 CELL LINE; ADIPOCYTE; ADIPOGENESIS; AGONISTS; ANIMAL; BONE DEVELOPMENT; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HYPERGLYCEMIA; METABOLISM; MOUSE; OSTEOBLAST; PHOSPHORYLATION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; BENZAMIDES; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE 5; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; HYPERGLYCEMIA; INDOLES; MICE; OSTEOBLASTS; OSTEOGENESIS; PHOSPHORYLATION; PPAR GAMMA; PROTEIN BINDING; THIAZOLIDINEDIONES;

EID: 84926295655     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12185     Document Type: Erratum

References (48)

1. Semple, R. K., Chatterjee, V. K. & O'Rahilly, S. PPAR gamma and human metabolic disease. J Clin Invest 116, 581-9 (2006).
2. Willson, T. M., Lambert, M. H. & Kliewer, S. A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70, 341-67 (2001).
3. Lecka-Czernik, B. et al. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143, 2376-84 (2002).
4. Ricote, M. & Glass, C. K. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771, 926-35 (2007).
5. Nesto, R. W. et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27, 256-63 (2004).
6. Martens, F. M., Visseren, F. L., Lemay, J., de Koning, E. J. & Rabelink, T. J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62, 1463-80 (2002).
7. Picard, F. & Auwerx, J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22, 167-97 (2002).
8. Gurnell, M., Savage, D. B., Chatterjee, V. K. & O'Rahilly, S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 88, 2412-21 (2003).
9. Patel, C., Wyne, K. L. & McGuire, D. K. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2, 61-6 (2005).
10. Tang, W. H. & Maroo, A. PPARgamma agonists: safety issues in heart failure. Diabetes Obes Metab 9, 447-54 (2007).
11. Shearer, B. G. & Billin, A. N. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 1771, 1082-93 (2007).
12. He, H. et al. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor gamma-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci 138, 468-81 (2014).
13. Schwartz, A. V. TZDs and Bone: A Review of the Recent Clinical Evidence. PPAR Res 2008, 297893 (2008).
14. Meier, C. et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 168, 820-5 (2008).
15. Grey, A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19, 129-37 (2008).
16. Gelman, L., Feige, J. N. & Desvergne, B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta 1771, 1094-107 (2007).
17. Argmann, C. A., Cock, T. A. & Auwerx, J. Peroxisome proliferator-activated receptor gamma: the more the merrier? Eur J Clin Invest 35, 82-92 (2005).
18. Cock, T. A., Houten, S. M. & Auwerx, J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 5, 142-7 (2004).
19. Gronemeyer, H., Gustafsson, J. A. & Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3, 950-64 (2004).
20. Knouff, C. & Auwerx, J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25, 899-918 (2004).
21. Gregoire, F. M. et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol 23, 975-88 (2009).
22. Minoura, H. et al. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. Diabetes Obes Metab 9, 369-78 (2007).
23. Li, Y. et al. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. J Biol Chem 283, 9168-76 (2008).
24. Liu, W. et al. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulators. J Med Chem 54, 8541-54 (2011).
25. Chang, C. H. et al. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur J Pharmacol 584, 192-201 (2008).
26. Berger, J. P. et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 17, 662-76 (2003).
27. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-6 (2010).
28. Houtkooper, R. H. & Auwerx, J. Obesity: New life for antidiabetic drugs. Nature 466, 443-4 (2010).
29. Guasch, L. et al. Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. PLoS One 7, e50816 (2012).
30. Cadoudal, T. et al. Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue. Diabetes 57, 2272-9 (2008).
31. Masuzaki, H. et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294, 2166-70 (2001).
32. Peng, Y. et al . Characterization of Osterix protein stability and physiological role in osteoblast differentiation. PLoS One 8, e56451 (2013).
33. Liu, F., Malaval, L. & Aubin, J. E. Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation. J Cell Sci 116, 1787-96 (2003).
34. Li, J. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97, 1566-71 (2000).
35. Yu, S. & Reddy, J. K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta 1771, 936-51 (2007).
36. Grana, X. et al. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A 91, 3834-8 (1994).
37. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395, 137-43 (1998).
38. Bays, H., Mandarino, L. & DeFronzo, R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89, 463-78 (2004).
39. Carmona, M. C. et al. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects. Diabetes 56, 2797-808 (2007).
40. Zhang, F., Lavan, B. E. & Gregoire, F. M. Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res 2007, 32696 (2007).
41. Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-81 (2011).
42. Malik, S. et al. Structural and functional organization of TRAP220, the TRAP/mediator subunit that is targeted by nuclear receptors. Mol Cell Biol 24, 8244-54 (2004).
43. Lin, J., Handschin, C. & Spiegelman, B. M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1, 361-70 (2005).
44. Burgermeister, E. et al. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20, 809-30 (2006).
45. Benson, S. C. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43, 993-1002 (2004).
46. Rocchi, S. et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8, 737-47 (2001).
47. Bruning, J. B. et al. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15, 1258-71 (2007).
48. Li, N. et al. Identification of a selective agonist for liver X receptor alpha (LXRalpha) via screening of a synthetic compound library. J Biomol Screen 19, 566-74 (2014).